← Journal search
JOURNAL PROFILE
Download details (PDF) ↓

Pharmacoepidemiology and Drug Safety (ISSN 1099-1557, 1053-8569) is a journal published by Wiley in the United Kingdom. It covers Medicine, Pharmacology (medical) and Epidemiology. It is indexed in Scopus, Web of Science, MEDLINE, PubMed and HEC. Recorded metrics: impact factor 2.6, Scopus Q2, Web of Science Q3, CiteScore 3.8 and HEC W-Category. Article processing charge: USD 4,880. This profile brings together the journal's ISSN, publisher, country, subject area, HEC category, Scopus data, SJR and SCImago rank, Web of Science data, impact factor, indexing, open access status, APC, aims and scope, about the journal, author instructions, journal website and registration details from the most reputable indexes, in one place.

Journal title

Pharmacoepidemiology and Drug Safety

ISSN
1099-1557, 1053-8569
Subject area
MedicinePharmacology (medical)Epidemiology
Indexed
ScopusWeb of ScienceMEDLINEPubMedHEC
Scopus Quartile
Q2
WoS Quartile
Q3
Impact Factor
2.6
Country
United Kingdom
Publisher
Wiley
SJR
1.041
Open access
No
APC (USD)
4880
About the journal
Pharmacoepidemiology and Drug Safety is the Official Journal of the International Society for Pharmacoepidemiology. The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, post-marketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
Aims and Scope
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, post-marketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
SCImago Ranking
4578
HEC
W-Category
Journal Website
onlinelibrary.wiley.com/loi/10991557 ↗
Registered In
1992
Instructions for Authors URL
onlinelibrary.wiley.com/page/journal/10991557/homepage/forauthors.html ↗
Average Time To Publication After Submission (In Weeks)
—
APC Information URL
onlinelibrary.wiley.com/page/journal/10991557/homepage/open-access ↗
Waiver policy
—
Scopus URL
www.scopus.com/sourceid/21166 ↗
Scopus Cite Score
3.8
WoS Status
Science Citation Index Expanded (SCIE)

Record last updated . Check current status at HEC HJRS, Scopus and the Web of Science Master Journal List before submitting. About our data.

Quick answers about Pharmacoepidemiology and Drug Safety

Is Pharmacoepidemiology and Drug Safety HEC recognised?

Yes. The catalogue records Pharmacoepidemiology and Drug Safety in HEC category W of the HEC Journal Recognition System, where W is the highest and Y the lowest category. Confirm the current category on HEC's HJRS website before you submit.

Is Pharmacoepidemiology and Drug Safety indexed in Scopus?

Yes. Pharmacoepidemiology and Drug Safety is listed as Scopus-indexed, in quartile Q2, with a CiteScore of 3.8. Check its current status on the Scopus Sources page.

Is Pharmacoepidemiology and Drug Safety in Web of Science?

Yes. Pharmacoepidemiology and Drug Safety is listed as a Web of Science journal in the Science Citation Index Expanded (SCIE), with Web of Science quartile Q3. Confirm on Clarivate's Master Journal List.

What is the impact factor of Pharmacoepidemiology and Drug Safety?

The recorded journal impact factor of Pharmacoepidemiology and Drug Safety is 2.6. Clarivate updates impact factors every year in Journal Citation Reports.

Is Pharmacoepidemiology and Drug Safety open access, and what does it charge?

Pharmacoepidemiology and Drug Safety is not recorded as fully open access and its APC is USD 4,880. Fees change, so check the journal's website before you submit.

Who publishes Pharmacoepidemiology and Drug Safety?

Pharmacoepidemiology and Drug Safety is published by Wiley in United Kingdom, under ISSN 1099-1557 and 1053-8569.

Research profile

Main research topics: Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical Practices and Patient Outcomes, Pharmaceutical industry and healthcare, Medical Coding and Health Information, Pharmacy and Medical Practices, Statistical Methods in Epidemiology.

Source: OpenAlex (CC0), retrieved 21 November 2026. Counts cover works OpenAlex has indexed and differ from Scopus and Web of Science.

Browse similar journals

Find Journal